News
MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment of MaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer.
A new SARS-CoV-2 variant, Nimbus or NB.1.8.1, is drawing attention due to rising transmission in parts of Asia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback